Legal & General Group
LFCR icon

Legal & General Group’s Lifecore Biomedical LFCR Stock Holding History

Legal & General Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.93K Sell
2,401
-276
-10% -$1.91K ﹤0.01% 3208
2025
Q4 		$21.9K Sell
2,677
-130
-5% -$962 ﹤0.01% 2984
2025
Q3 		$20.7K Hold
2,807
– – ﹤0.01% 3020
2025
Q2 		$22.8K Buy
2,807
+406
+17% +$2.74K ﹤0.01% 2957
2025
Q1 		$16.9K Buy
2,401
+550
+30% +$3.42K ﹤0.01% 3002
2024
Q4 		$13.8K Hold
1,851
– – ﹤0.01% 3168
2024
Q3 		$9.13K Hold
1,851
– – ﹤0.01% 3287
2024
Q2 		$9.54K Buy
+1,851
New +$11K ﹤0.01% 3306
2023
Q2 		– Sell
-2,645
Closed -$9.98K – 3468
2023
Q1 		$9.98K Hold
2,645
– – ﹤0.01% 3209
2022
Q4 		$17.2K Hold
2,645
– – ﹤0.01% 3187
2022
Q3 		$24K Buy
2,645
+406
+18% +$4.13K ﹤0.01% 3162
2022
Q2 		$22K Buy
2,239
+178
+9% +$1.76K ﹤0.01% 3201
2022
Q1 		$24K Hold
2,061
– – ﹤0.01% 3191
2021
Q4 		$23K Sell
2,061
-9,339
-82% -$90.6K ﹤0.01% 3229
2021
Q3 		$105K Buy
11,400
+5,795
+103% +$63.1K ﹤0.01% 2835
2021
Q2 		$63K Sell
5,605
-228
-4% -$2.63K ﹤0.01% 2883
2021
Q1 		$62K Hold
5,833
– – ﹤0.01% 2756
2020
Q4 		$63K Hold
5,833
– – ﹤0.01% 2737
2020
Q3 		$56K Sell
5,833
-1,124
-16% -$10.7K ﹤0.01% 2657
2020
Q2 		$55K Hold
6,957
– – ﹤0.01% 2700
2020
Q1 		$61K Sell
6,957
-849
-11% -$8.84K ﹤0.01% 2539
2019
Q4 		$88K Buy
7,806
+564
+8% +$6K ﹤0.01% 2633
2019
Q3 		$79K Buy
7,242
+2,606
+56% +$28.4K ﹤0.01% 2600
2019
Q2 		$44K Hold
4,636
– – ﹤0.01% 2827
2019
Q1 		$57K Sell
4,636
-647
-12% -$7.9K ﹤0.01% 2664
2018
Q4 		$62K Buy
5,283
+1,401
+36% +$19.2K ﹤0.01% 2612
2018
Q3 		$56K Hold
3,882
– – ﹤0.01% 2717
2018
Q2 		$58K Sell
3,882
-679
-15% -$9.44K ﹤0.01% 2687
2018
Q1 		$60K Sell
4,561
-2,726
-37% -$35.8K ﹤0.01% 2666
2017
Q4 		$90K Buy
7,287
+498
+7% +$6.29K ﹤0.01% 2632
2017
Q3 		$89K Sell
6,789
-563
-8% -$7.42K ﹤0.01% 2708
2017
Q2 		$108K Hold
7,352
– – ﹤0.01% 2565
2017
Q1 		$87K Sell
7,352
-324
-4% -$4.1K ﹤0.01% 2617
2016
Q4 		$107K Buy
7,676
+3,569
+87% +$49.4K ﹤0.01% 2524
2016
Q3 		$55K Hold
4,107
– – ﹤0.01% 2473
2016
Q2 		$43K Hold
4,107
– – ﹤0.01% 2548
2016
Q1 		$44K Hold
4,107
– – ﹤0.01% 2466
2015
Q4 		$49K Hold
4,107
– – ﹤0.01% 2470
2015
Q3 		$47K Hold
4,107
– – ﹤0.01% 2485
2015
Q2 		$59K Hold
4,107
– – ﹤0.01% 2462
2015
Q1 		$57K Hold
4,107
– – ﹤0.01% 2421
2014
Q4 		$58K Hold
4,107
– – ﹤0.01% 2345
2014
Q3 		$51K Buy
+4,107
New +$51.3K ﹤0.01% 2372

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group's LFCR Position: Q1 2026 in Review

Legal & General Group reduced its Lifecore Biomedical (LFCR) stake by 10% in Q1 2026, selling an estimated $1.91K and leaving 2,401 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3208.

Legal & General Group first reported a position in LFCR in Q3 2014 and has held it in 43 quarters since. The position peaked at $108K in Q2 2017. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Legal & General Group held 2,401 shares of Lifecore Biomedical worth $8.93K as of Q1 2026.
  • Legal & General Group sold 276 Lifecore Biomedical shares in Q1 2026, an estimated $1.91K.
  • Lifecore Biomedical made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3208 holding.
  • Legal & General Group first reported a position in Lifecore Biomedical in Q3 2014 and has held it in 43 quarters since.
  • Legal & General Group's Lifecore Biomedical position peaked at $108K in Q2 2017.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.